The structural heart diseases are the
idiosyncrasies in the heart by birth or which enhance later in life due to the
aging infections, or injury, which leads to the heart attacks and the other
fundamental ailments. The term structural heart disease includes a variety of
ailments connected with the congestive heart failure (CHF) and embolic stroke,
together with the atrial defect (ASD), ventricular septal defect (VSD), patent
foramen ovale (PFO) and left atrial appendix (LAA). Moreover, the significant
increase in the healthcare spending, rise in the number of outpatient
procedures, and market development opportunities in emerging nations are
delivering an opportunity for the market growth.
According to the report analysis, ‘Global
Structural Heart Devices Market Forecast up to 2024’ states that there
are several key players which are presently functioning in this sector more
actively for leading the fastest market growth and registering the high value
of market share across the globe during the short span of time while employing
the skilled healthcare professionals, increase in the minimally invasive
surgery for the structural heart diseases and augmenting the prevalence of the
cardiovascular disorders includes abbott Laboratories, Boston Scientific
Corporation, Medtronic plc, Edward LifeSciences Corp., and LivaNova PLC. Lepu
Medical Technology, CryoLife, Inc., JenaValve Technologies GmbH, TTK
Healthcare, and Braile Biomedica. However, many of the potential players in the
market are flooding into the TMVR arena, the market can suppose the robust and
innovative state-of-the-art technologies, making the intense competition in the
coming years. A Canadian company, NeoVasc has enhanced a novel technology
device named Tiara to substitute any regurgitation of mitral valves. Not only
has this, the mergers and acquisitions has been the foremost strategy followed
by superior players in the market to continue their leadership in the market.
The Edwards set its position in the mitral valve market by purchasing the
Harpoon Medical, the DMR-aimed chordal surgical mitral valve repair startup
company for ~USD 100M upfront.
The Global Structural Heart Devices
Market is predicted to observe a CAGR of 10.2% during the forecast period of
2018-2024. Moreover, the market of global structural heart devices is segmented
into different sectors which majorly involves type, end users and regions.
Whereas, based on the region, the market of structural heart devices is spread
across the globe which majorly involves North America, Europe, Asia Pacific,
and Rest of the World (ROW). However, the North America registers for the
principal share of the structural heart devices market, followed by Europe,
Asia Pacific, and Rest of the World. More than 40% of the market is effectively
attained by North America regions, with the US being the foremost contributor
to the market growth in 2017.
Additionally, on the basis of end
user, the market is sectored into hospitals, ambulatory surgical centers, and
cardiac centers. Whereas, the hospitals are the principal among end-users and
are favored for the treatment owing to the benefits such as availability of
surgery specialists, reimbursement facility, and obtainability of high end
equipment for the surgery.
Although, the significant growth in
the aging population, growing prevalence of cardiovascular diseases, and
effective increase in minimally invasive surgery for structural heart diseases
are the aspects aiding for the growth of the structural heart devices market.
therefore, in the coming years, it is predicted that the market of structural
heart devices will increase around the globe more positively over the recent
few years.
To know more, click on the link
below:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91-9015378249
